Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CancerCode Informed Targeted Therapies in NSCLC
NCT02132884Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Mar 2015
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Progression Free Survival at 3 months. Started Mar 2015; status: terminated.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02132884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132884.